{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:02:41Z","timestamp":1789398161725,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40801-026-00565-7","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:13:05Z","timestamp":1783527185000},"page":"373-382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Complications and Occurrence of Exacerbations in Patients with Myasthenia Gravis Treated with Oral Corticosteroids"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5220-7669","authenticated-orcid":false,"given":"Zhiwen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9547-7501","authenticated-orcid":false,"given":"Louis","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8335-3009","authenticated-orcid":false,"given":"Jacqueline","family":"Pesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7070-7835","authenticated-orcid":false,"given":"Alicia K.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4219-4777","authenticated-orcid":false,"given":"Zia","family":"Choudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-3448","authenticated-orcid":false,"given":"Nizar","family":"Souayah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"issue":"12","key":"565_CR1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179742","volume":"134","author":"HJ Kaminski","year":"2024","unstructured":"Kaminski HJ, Sikorski P, Coronel SI, Kusner LL. Myasthenia gravis: the future is here. J Clin Invest. 2024;134(12):e179742. https:\/\/doi.org\/10.1172\/JCI179742.","journal-title":"J Clin Invest"},{"issue":"7","key":"565_CR2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3390\/cells8070671","volume":"8","author":"I Koneczny","year":"2019","unstructured":"Koneczny I, Herbst R. Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture. Cells. 2019;8(7):671. https:\/\/doi.org\/10.3390\/cells8070671.","journal-title":"Cells"},{"issue":"11","key":"565_CR3","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","volume":"116","author":"BM Conti-Fine","year":"2006","unstructured":"Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116(11):2843\u201354. https:\/\/doi.org\/10.1172\/JCI29894.","journal-title":"J Clin Invest"},{"issue":"8","key":"565_CR4","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1136\/jnnp.74.8.1105","volume":"74","author":"A Vincent","year":"2003","unstructured":"Vincent A, Clover L, Buckley C, Grimley Evans J, Rothwell PM. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry. 2003;74(8):1105\u20138. https:\/\/doi.org\/10.1136\/jnnp.74.8.1105.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"565_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"18","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;18(10):46. https:\/\/doi.org\/10.1186\/1471-2377-10-46.","journal-title":"BMC Neurol"},{"issue":"2","key":"565_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/mus.28006","volume":"69","author":"E Rodrigues","year":"2024","unstructured":"Rodrigues E, Umeh E, Aishwarya, Navaratnarajah N, Cole A, Moy K. Incidence and prevalence of myasthenia gravis in the United States: a claims-based analysis. Muscle Nerve. 2024;69(2):166\u201371. https:\/\/doi.org\/10.1002\/mus.28006.","journal-title":"Muscle Nerve"},{"key":"565_CR7","doi-asserted-by":"publisher","first-page":"1339167","DOI":"10.3389\/fneur.2024.1339167","volume":"15","author":"Y Ye","year":"2024","unstructured":"Ye Y, Murdock DJ, Chen C, Liedtke W, Knox CA. Epidemiology of myasthenia gravis in the United States. Front Neurol. 2024;15:1339167. https:\/\/doi.org\/10.3389\/fneur.2024.1339167.","journal-title":"Front Neurol"},{"issue":"2","key":"565_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40259-024-00701-1","volume":"39","author":"L Gerischer","year":"2025","unstructured":"Gerischer L, Doksani P, Hoffmann S, Meisel A. New and emerging biological therapies for myasthenia gravis: a focussed review for clinical decision-making. BioDrugs. 2025;39(2):185\u2013213. https:\/\/doi.org\/10.1007\/s40259-024-00701-1.","journal-title":"BioDrugs"},{"issue":"12","key":"565_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.809999","volume":"18","author":"G Phillips","year":"2022","unstructured":"Phillips G, Abreu C, Goyal A, Li Y, Whangbo A, Gelinas D, et al. Real-world healthcare resource utilization and cost burden assessment for adults with generalized myasthenia gravis in the United States. Front Neurol. 2022;18(12):809999. https:\/\/doi.org\/10.3389\/fneur.2021.809999.","journal-title":"Front Neurol"},{"issue":"3","key":"565_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","volume":"15","author":"J Sussman","year":"2015","unstructured":"Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D. Myasthenia gravis: Association of British Neurologists\u2019 management guidelines. Pract Neurol. 2015;15(3):199\u2013206. https:\/\/doi.org\/10.1136\/practneurol-2015-001126.","journal-title":"Pract Neurol"},{"issue":"6","key":"565_CR11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/mus.22212","volume":"44","author":"JT Guptill","year":"2011","unstructured":"Guptill JT, Marano A, Krueger A, Sanders DB. Cost analysis of myasthenia gravis from a large U.S. insurance database. Muscle Nerve. 2011;44(6):907\u201311. https:\/\/doi.org\/10.1002\/mus.22212.","journal-title":"Muscle Nerve"},{"issue":"12","key":"565_CR12","doi-asserted-by":"publisher","first-page":"175628641983224","DOI":"10.1177\/1756286419832242","volume":"1","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019;1(12):1756286419832242. https:\/\/doi.org\/10.1177\/1756286419832242.","journal-title":"Ther Adv Neurol Disord"},{"key":"565_CR13","unstructured":"National Institute of Neurological Disorders and Stroke (NINDS). Myasthenia gravis. Available from: https:\/\/www.ninds.nih.gov\/health-information\/disorders\/myasthenia-gravis#:~:text=Sometimes%20the%20muscles%20that%20control,trigger%20for%20their%20myasthenic%20crisis. Accessed 16 Dec 2025."},{"issue":"1","key":"565_CR14","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0108","volume":"13","author":"J Pisc","year":"2024","unstructured":"Pisc J, Ting A, Skornicki M, Sinno O, Lee E. Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data. J Comp Eff Res. 2024;13(1):e230108. https:\/\/doi.org\/10.57264\/cer-2023-0108.","journal-title":"J Comp Eff Res."},{"key":"565_CR15","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.2147\/COPD.S433326","volume":"18","author":"G Tse","year":"2023","unstructured":"Tse G, Emmanuel B, Ariti C, et al. A long-term study of adverse outcomes associated with oral corticosteroid use in COPD. Int J Chron Obstruct Pulmon Dis. 2023;18:2565\u201380.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"12","key":"565_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061476","volume":"12","author":"S Kulkarni","year":"2022","unstructured":"Kulkarni S, Durham H, Glover L, Ather O, Phillips V, Nemes S, et al. Metabolic adverse events associated with systemic corticosteroid therapy-a systematic review and meta-analysis. BMJ Open. 2022;12(12):e061476. https:\/\/doi.org\/10.1136\/bmjopen-2022-061476.","journal-title":"BMJ Open"},{"issue":"12","key":"565_CR17","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1080\/02770903.2018.1539100","volume":"56","author":"K Al Efraij","year":"2019","unstructured":"Al Efraij K, Johnson KM, Wiebe D, Sadatsafavi M, FitzGerald JM. A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma. J Asthma. 2019;56(12):1334\u201346. https:\/\/doi.org\/10.1080\/02770903.2018.1539100.","journal-title":"J Asthma"},{"issue":"6","key":"565_CR18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/87551225221116266","volume":"38","author":"EJ Koshi","year":"2022","unstructured":"Koshi EJ, Young K, Mostales JC, Vo KB, Burgess LP. Complications of corticosteroid therapy: a comprehensive literature review. J Pharm Technol. 2022;38(6):360\u20137. https:\/\/doi.org\/10.1177\/87551225221116266.","journal-title":"J Pharm Technol"},{"key":"565_CR19","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1007\/s00415-023-11925-6","volume":"270","author":"JB Chanson","year":"2023","unstructured":"Chanson JB, Bouhour F, Aub\u00e9-Nathier AC, Mallaret M, Vial C, Hacquard A, et al. Myasthenia gravis treatment in the elderly presents with a significant iatrogenic risk: a multicentric retrospective study. J Neurol. 2023;270:5819\u201326. https:\/\/doi.org\/10.1007\/s00415-023-11925-6.","journal-title":"J Neurol"},{"key":"565_CR20","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.933296","volume":"27","author":"S Johnson","year":"2021","unstructured":"Johnson S, Katyal N, Narula N, Govindarajan R. Adverse side effects associated with corticosteroid therapy: a study in 39 patients with generalized myasthenia gravis. Med Sci Monit. 2021;27:e933296. https:\/\/doi.org\/10.12659\/MSM.933296.","journal-title":"Med Sci Monit"},{"issue":"28","key":"565_CR21","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661\u201379. https:\/\/doi.org\/10.1002\/sim.6607.","journal-title":"Stat Med"},{"key":"565_CR22","volume-title":"Users\u2019 guide statistics, Version 9.4","author":"Statistical Analysis Software (SAS)","year":"2013","unstructured":"Statistical Analysis Software (SAS). Users\u2019 guide statistics, Version 9.4. Cary: SAS Institute Inc; 2013."},{"issue":"1","key":"565_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40120-022-00408-x","volume":"12","author":"K Jackson","year":"2023","unstructured":"Jackson K, Parthan A, Lauher-Charest M, Broderick L, Law N, Barnett C. Understanding the symptom burden and impact of myasthenia gravis from the patient\u2019s perspective: a qualitative study. Neurol Ther. 2023;12(1):107\u201328. https:\/\/doi.org\/10.1007\/s40120-022-00408-x.","journal-title":"Neurol Ther"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00565-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00565-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00565-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:04:05Z","timestamp":1789394645000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00565-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["565"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00565-7","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"16 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zhiwen Liu, Louis Jackson, Jacqueline Pesa, Alicia K. Campbell, and Zia Choudhry are employees and stockholders of Johnson & Johnson. Nizar Souayah has no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of interest\/Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki (1964 and later amendments). This study was reviewed and determined to be exempt from institutional review board review pursuant to the terms of the U.S. Department of Health and Human Services Policy for Protection of Human Research Subjects at 45 C.F.R. \u00a746.104(d).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data were de-identified; therefore, no informed consent was required for this study, and it was also determined to be exempt from institutional review board review pursuant to the terms of the U.S. Department of Health and Human Services Policy for Protection of Human Research Subjects at 45 C.F.R. \u00a746.104(d).","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data sharing policy of Johnson & Johnson is available at\n                      \n                      . These data were made available by Optum and used under license for the current study and are not publicly available. Other researchers should contact\n                      \n                      .","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ZL: conceptualization; data curation; formal analysis; writing (original draft preparation); writing (review and editing). LJ: conceptualization; formal analysis; writing (original draft preparation); writing (review and editing). JP: conceptualization; formal analysis; writing (original draft preparation); writing (review and editing). AKC: conceptualization; formal analysis; writing (original draft preparation); writing (review and editing). ZC: writing (original draft preparation); writing (review and editing). NS: formal analysis; writing (original draft preparation); writing (review and editing). All authors reviewed and approved the final version of the manuscript.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}